Aurobindo Pharma dips on USFDA procedural observations on Hyderabad unit

The stock dipped 4.7% to Rs 633 on BSE in late noon deal.

Aurobindo Pharma dipped 4.7% to Rs 633 on BSE in late noon deal after the company said the US drug regulator issued six large procedural observations for its Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad.

The United States Food and Drug Administration (USFDA) had conducted an inspection at the company’s Unit III a formulation manufacturing facility located at Bachupally, Hyderabad from 10th April, 2017 to 18th April, 2017.

“At the end of the inspection, we have been issued a Form 483 with 6 observations. The observations are all on procedural improvements. None of the observations